Biotech startup Tenex Health Inc. received commitments for $1.7 million in equity of an anticipated $2 million fund-raise, according to a regulatory filing.
The funding, with a minimum of $25,000 per investor, comes from 26 investors, according to the document.
In March the company reported having raised $1.3 million of the $2 million goal.
Because Tenex doesn’t have a website and was founded last year, details on the start-up are scarce. The company is apparently developing treatments for sports-related injuries like tendinitis.
CEO Jagi Gill didn’t return a call.
Gill is a long-time medical device executive in the Minnesota. He formerly worked at Mayo Clinic&’s department of neurology and Boston Scientific Corp. where he was a top marketing and business development executive at its cardiovascular and neuromodulation units.
